Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label VELCADE Retreatment in Multiple Myeloma
2005-005819-26Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Best response to VELCADE retreatment. Started Feb 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-005819-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005819-26.